Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
Next >
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
October 03, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
September 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
September 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Cantor Global Healthcare Conference
September 25, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual and Special Meeting of Shareholders
September 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
September 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
September 05, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Acquire Small Pharma Inc.
August 28, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
DMTTF
TSX-V:DMT
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
August 17, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
August 15, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports First Quarter Financial Results and Recent Business Highlights
August 14, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Closing of Overnight Marketed Public Offering of Units
August 04, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
August 02, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
August 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Overnight Marketed Public Offering of Units
July 31, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
July 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
July 24, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
July 20, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
July 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in PSYCH Symposium London 2023
June 30, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
June 29, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
June 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
June 27, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
June 21, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Provides Corporate Update
June 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
June 05, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.